Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
Status:
Completed
Trial end date:
2016-07-04
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine whether delamanid is effective in the treatment of
multidrug-resistant tuberculosis (MDR TB) in combination with other MDR TB medications during
6 months of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.